Cover Image
Market Research Report - 244300

AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022

Published by GlobalData
Published Content info 37 Pages
Price
Back to Top
AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022
Published: April 30, 2012 Content info: 37 Pages
Description

Summary

GlobalData's pharmaceuticals report, "AAB-001 (bapineuzumab) (Alzheimer's disease) - Analysis and Forecasts to 2022" provides AAB-001 global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of AAB-001 including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of AAB-001 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2014-2022 for AAB-001

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

AAB-001, bapineuzumab, anti-amyloid monoclonal antibody, Johnson & Johnson, Pfizer, Alzheimer's disease

Table of Contents

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Alzheimer's Disease
  • 2.2. Symptoms
  • 2.3. Alzheimer's disease Market
  • 2.4. Epidemiology
  • 2.5. Etiology
    • 2.5.1. Age
    • 2.5.2. Family History
    • 2.5.3. Genetics
  • 2.6. Economic Impact of Alzheimer's disease
  • 2.7. GlobalData Report Guidance

3. Alzheimer's disease: Market Characterization

  • 3.1. Alzheimer's disease Market
  • 3.2. Alzheimer's disease Market Forecasts and CAGR
  • 3.3. Drivers and Barriers of Alzheimer's disease Therapeutics Market
    • 3.3.1. Ageing Population
    • 3.3.2. Patent Expiries
    • 3.3.3. New Product Launches
    • 3.3.4. High Unmet Need

4. Classification of Alzheimer's disease

  • 4.1. Stage 1 (Mild)
  • 4.2. Stage 2 (Moderate)
  • 4.3. Stage 3 (Severe)

5. Treatment for Alzheimer's disease

  • 5.1. Cognitive Symptoms
    • 5.1.1. Cholinesterase Inhibitors (ChEIs)
    • 5.1.2. NMDA antagonists
    • 5.1.3. Other Pharmacotherapeutic Agents
  • 5.2. Behavioural Symptoms and Mood Disorders
    • 5.2.1. Non-pharmacological Approaches
    • 5.2.2. Prescription Medicines
  • 5.3. Next-generation Drugs
    • 5.3.1. Disease Modifying Agents
    • 5.3.2. Tau-directed Therapies
    • 5.3.3. Other Therapies

6. AAB-001

  • 6.1. Introduction
  • 6.2. Mechanism of Action
  • 6.3. Clinical Studies
    • 6.3.1. Bapineuzumab (AAB-001) in Patients with Mild to Moderate Alzheimer's disease (ApoE4 Non-Carrier & ApoE4 Carrier), Phase - II
    • 6.3.2. Phase III AAB-001 in Patients with Mild to Moderate Alzheimer's disease (ApoE4 Non-Carrier)
  • 6.4. Factors Affecting Sales of AAB-001
    • 6.4.1. Disease Modifying Potential
    • 6.4.2. First in Immunotherapy Class
    • 6.4.3. Patent Expiry of Existing Marketed Drugs
    • 6.4.4. Clinical Trials for Other Dosage Forms of AAB-001
    • 6.4.5. Fast Track Regulatory Status with FDA
    • 6.4.6. Competition with LY2062430
  • 6.5. Drug Evaluation
    • 6.5.1. Drug Risk Benefit Score
    • 6.5.2. Intensity of Competition
  • 6.6. Sales Forecast
    • 6.6.1. Target Patient Pool for AAB-001
    • 6.6.2. Dosing
    • 6.6.3. Market Penetration
    • 6.6.4. Sales Projections of AAB-001

7. Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Research Methodology
    • 7.3.1. Coverage
    • 7.3.2. Secondary Research
    • 7.3.3. Forecasting
    • 7.3.4. Number of Patients Approved to Take the Drug
    • 7.3.5. Net Penetration of Drug
    • 7.3.6. Net Annual Dosing
    • 7.3.7. Annual Cost of Therapy
  • 7.4. Drug Sales Estimates Model
  • 7.5. Contact Us
  • 7.6. Disclaimer
  • 7.7. Sources

List of Tables

  • Table 1: Alzheimer's disease, World, Major Pipeline Products in Phase III
  • Table 2: Mild Stage Alzheimer's disease, Abilities Affected and Their Typical Symptoms
  • Table 3: Moderate Stage Alzheimer's disease, Abilities Affected and Their Typical Symptoms
  • Table 4: Severe Stage Alzheimer's disease, Abilities Affected and Their Typical Symptoms
  • Table 5: Non-pharmacological Approaches for Behavioural Symptoms and Mood Disorders
  • Table 6: Experimental Disease Modifying Drugs in Phase III for Alzheimer's disease
  • Table 7: AAB-001, Phase II, Clinical Trial Results
  • Table 8: AAB-001, Alzheimer's disease, Drug Risk Benefit Score
  • Table 9: AAB-001, Alzheimer's disease, Global, Sales Forecasts ($m), 2014-2022
  • Table 10: AAB-001, Alzheimer's disease, The US, Sales Forecasts ($m), 2014-2022
  • Table 11: AAB-001, Alzheimer's disease, UK, Sales Forecasts ($m), 2015-2022
  • Table 12: AAB-001, Alzheimer's disease, France, Sales Forecasts ($m), 2015-2022
  • Table 13: AAB-001, Alzheimer's disease, Germany, Sales Forecasts ($m), 2015-2022
  • Table 14: AAB-001, Alzheimer's disease, Italy, Sales Forecasts ($m), 2015-2022
  • Table 15: AAB-001, Alzheimer's disease, Spain, Sales Forecasts ($m), 2015-2022
  • Table 16: AAB-001, Alzheimer's disease, Japan, Sales Forecasts ($m), 2015-2022

List of Figures

  • Figure 1: Brain Affected by Alzheimer's disease
  • Figure 2: Estimated Lifetime Risks for Alzheimer's disease by Age and Sex, The US
  • Figure 3: Estimated Number of Cases of Alzheimer's disease (million), The US
  • Figure 4: Changes in Selected Causes of Death, The US, 2000-2008
  • Figure 5: Alzheimer's Disease, Global, Market Size Forecasts ($bn), 2011-2022
  • Figure 6: Drug Model Diagram of AAB-001
  • Figure 7: AAB-001, Alzheimer's disease, Global, Sales Forecasts ($m), 2014-2022
  • Figure 8: AAB-001, Alzheimer's disease, The US, Sales Forecasts ($m), 2014-2022
  • Figure 9: AAB-001, Alzheimer's disease, UK, Sales Forecasts ($m), 2015-2022
  • Figure 10: AAB-001, Alzheimer's disease, France, Sales Forecasts ($m), 2015-2022
  • Figure 11: AAB-001, Alzheimer's disease, Germany, Sales Forecasts ($m), 2015-2022
  • Figure 12: AAB-001, Alzheimer's disease, Italy, Sales Forecasts ($m), 2015-2022
  • Figure 13: AAB-001, Alzheimer's disease, Spain, Sales Forecasts ($m), 2015-2022
  • Figure 14: AAB-001, Alzheimer's disease, Japan, Sales Forecasts ($m), 2015-2020
  • Figure 15: AAB-001, Alzheimer's disease, Sales Distribution by Country (%), 2022
  • Figure 16: Patients Approved for the Drug
Back to Top